Title 21 › Chapter 9— FEDERAL FOOD, DRUG, AND COSMETIC ACT › Subchapter V— DRUGS AND DEVICES › Part I— Nonprescription Sunscreen and Other Active Ingredients › § 360fff–6
Sponsors who filed, before November 26, 2014, an application asking the FDA to find a non-sunscreen drug “generally recognized as safe and effective” (GRASE) can ask the FDA for a written review plan. The sponsor must ask within 180 calendar days of November 26, 2014. Within one year of November 26, 2014, the FDA must give each requesting sponsor a framework that shows the calendar-day timelines for each available review route. Sponsors then have 60 calendar days after getting the framework to pick one of four review paths the FDA offers (two use the FDA’s existing monograph rules, and two use a mix of an initial filing check and those other processes). If a sponsor makes the choice, the FDA will follow that path and timeline and confirm it in writing. If the sponsor does not ask for a framework or does not choose a path in time, the FDA will use the timelines set in the final regulations when those are completed. During review, the FDA can switch to a different path only if it proposes the change in writing and the sponsor agrees in writing. If a sponsor chooses certain paths, the FDA may fold the final decision into a future regulation, and that decision ends when the regulation goes into effect. The FDA must report to the Senate Health, Education, Labor, and Pensions Committee and the House Energy and Commerce Committee no later than 18 months after November 26, 2014. The report must list pending applications and the calendar-day timelines for each review. The FDA must also publish proposed rules setting review timelines for applications submitted after November 26, 2014 no later than 18 months after that date, allow at least 60 calendar days for public comment, publish final rules at least 30 calendar days before they take effect, and finish the final rules no later than 27 months after November 26, 2014. All timelines must be reasonable, may vary with the application’s content and complexity, reflect FDA public-health priorities, and take FDA resources into account.
Full Legal Text
Food and Drugs, Source: USLM XML via OLRC
Legislative History
Reference
Citation
21 U.S.C. § 360fff–6
Title 21, Food and Drugs
Last Updated
Apr 5, 2026
Release point: 119-73not60